Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPOLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPOLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPOLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPOLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPOLORE MOREBased on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. Particularly, we offer cytokines release assay service to help customers assess the function of their TCR-modified T cells by determining the cytokines releasing ability.
In recent years, T-cell therapy has yielded impressive clinical results in patients who had previously failed to standard treatments. Adoptively transferred T cells have the capacity to kill antigen-expressing tumor cells and thereby provide a direct cytolytic effector function. Several TCR gene-modified T-cell trials have shown successes. Adoptively transferred T cells not only can directly kill tumor cells to enable fast tumor reduction, but also can initiate late adaptive responses by other compartments of the immune system. TCRs on T-cell surfaces can specifically recognize peptide antigens presented by APCs, leading to the activation of T-cells and a series of functional outcomes such as cytokine production. The release of cytokines by T cells defines a significant part of their functional activity and their ability to produce multiple cytokines has been associated with beneficial immune responses. With the increasing of TCR gene-modified T-cell research and development, evaluating the cytokines release ability of TCR-modified T cells can be quite important for monitoring the function and efficiency.
Creative Biolabs commonly provides our clients the measurement methods including enzyme-linked immunospot assay (ELISpot), intracellular cytokine staining assay (ICS), and flow cytometry, but not limited to them. In response to viruses or tumor antigens, those successfully modified T cells can secrete higher levels of cytokines, such as IFN-γ, IL-12 and GM-CSF. Therefore, Creative Biolabs will focus on these kinds of cytokines and select appropriate methods for customers to analyze these released cytokines.
Fig.1 Illustration of the ELISPOT assay
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
